Recent Finacing
Recent Raise
NeRRe Therapeutics is a clinical-stage biopharma developing NK receptor antagonists, notably oral NK-1 antagonist orvepitant for chronic cough including IPF-related cough, and dual NK-1/3 candidate NT-814.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at NeRRe Therapeutics.
